Wake Forest Baptist to Participate in Clinical Trial of Brain Tumor Vaccine

Wake Forest Baptist Medical Center in Winston-Salem, N.C., is the only facility in the Southeast U.S. participating in a national clinical trial that tests the efficacy of a novel brain tumor vaccine. The vaccine will be tested in patients with newly diagnosed glioblastoma multiforme (GBM), the most aggressive and highest grade of malignant glioma. Wake Forest Baptist will treat at least 25 patients in this randomized, placebo-controlled phase II clinical trial of ICT-107. Nationwide, 20 sites are taking part in this trial.

Every patient enrolled in the study will undergo the current standard treatment for GBM, including surgery followed by radiation and chemotherapy. In addition, two-thirds of participants then will receive the experimental vaccine treatment, to be administered in the post-radiation phase of treatment, while the remaining one-third will get a “dummy” or placebo vaccine, plus standard therapy. For more information, click here to read the full release.